Coronavirus Disease 2019 (COVID-19) Vaccination in Pregnancy : Obstetrics & Gynecology

Secondary Logo

Journal Logo

Narrative Review

Coronavirus Disease 2019 (COVID-19) Vaccination in Pregnancy

Prabhu, Malavika MD; Riley, Laura E. MD

Author Information
Obstetrics & Gynecology ():10.1097/AOG.0000000000005100, January 17, 2023. | DOI: 10.1097/AOG.0000000000005100
  • Free
  • PAP

The rapid development of coronavirus disease 2019 (COVID-19) vaccines and the limited prospective data on COVID-19 vaccination in pregnancy has resulted in individuals, including pregnant individuals, being fearful of potential risks. The uptake of vaccination has been lower among pregnant individuals as compared with reproductive-aged nonpregnant individuals, with notable disparities by race and ethnicity.1,2 The most recent data from the Centers for Disease Control and Prevention (CDC) (as of December 31, 2022) show that 72% of pregnant individuals are fully vaccinated with the primary vaccine series.3 These findings are despite unequivocal data demonstrating increased risks of maternal adverse outcomes (intensive care unit [ICU] admission, mechanical ventilation, death) and fetal or neonatal adverse outcomes (preterm delivery, stillbirth) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy.4

The primary goal of coronavirus disease 2019 (COVID-19) vaccination is to prevent severe disease, hospitalization, and death due to COVID-19. Initial randomized controlled trial data for the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) mRNA vaccines demonstrated 91% and 93% efficacy, respectively, against laboratory-confirmed SARS-CoV-2 infection, with some decline in vaccine efficacy with time elapsed since the last dose.5,6 These initial studies were completed before the development of novel SARS-CoV-2 variants. Over the past 2 years, real-world experience and subsequent data have demonstrated lower vaccine efficacy against infection; thus, a bivalent booster targeting the native SARS-CoV-2 strain as well as the Omicron strain was developed.

In this narrative review, we provide evidence-based answers to common questions faced by clinicians caring for pregnant individuals. We discuss the efficacy of COVID-19 vaccines by summarizing the published literature on the maternal antibody response to vaccination and on the decreased risks of SARS-CoV-2 infection during pregnancy with vaccination, present the neonatal benefit of maternal vaccination, and highlight the documented safety profile of vaccination during pregnancy. We will focus primarily on mRNA-based vaccines, because these are the most available vaccines in the United States.


The American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal Medicine (SMFM), and the CDC all recommend COVID-19 vaccination at any point for individuals who are pregnant or may be pregnant in the future.7–9 mRNA vaccines are preferred, although any COVID-19 vaccine platform with U.S. Food and Drug Administration approval or emergency use authorization is acceptable.

For individuals who have not been vaccinated against COVID-19 before or during pregnancy and are not immunocompromised, an initial two-dose mRNA vaccine series constitutes the primary series. The primary series can be administered at any point in pregnancy. For individuals who previously have received a primary vaccine series with or without a monovalent booster outside of pregnancy, a bivalent booster dose should be administered 2 months after the completion of a primary series or 2 months after the last (monovalent) booster dose, regardless of the total number of COVID-19 vaccine doses a patient has received (Fig. 1).10,11

Fig. 1.:
Coronavirus disease 2019 (COVID-19) vaccination recommendations for pregnant persons, based on vaccination status prepregnancy. The recommended primary vaccination series is two doses of an mRNA-based vaccine for immunocompetent individuals and three doses of an mRNA-based vaccine for immunocompromised individuals. A bivalent mRNA booster is recommended 2 months after the last vaccine dose for all individuals.

Special circumstances exist in which the COVID-19 vaccination schedule deviates from that described above. In immunocompromised patients (such as individuals with organ transplant, use of immunosuppressing medications, congenital immunosuppressing conditions, and other similar conditions), the primary vaccine series is a three-dose mRNA series, with the third dose administered 4 weeks after the second dose. A bivalent booster is recommended 2 months after completion of the three-dose primary series.10,11

During pregnancy, influenza and Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccinations are routinely recommended. Timing of COVID-19 vaccine administration is independent of the timing of influenza and Tdap vaccine administration, and co-administration is appropriate. Initial recommendations to separate COVID-19 vaccination from other vaccinations were motivated by the need to document COVID-19 vaccine–specific side effects and adverse effects. At present, only for recent vaccination against mpox (formerly monkeypox) is a delay of 4 weeks before a COVID-19 vaccine suggested.11

Up-to-date recommendations regarding COVID-19 vaccination can be found on the CDC website:


COVID-19 vaccination is directed against the SARS-CoV-2 spike (S) protein, and the vaccine-induced antibody is the anti-S antibody. SARS-CoV-2 infection also induces anti-S antibodies, in addition to other antibodies, such as anti-nucleocapsid (N) antibodies, that are not generated after vaccination alone. The typical response to an antigenic stimulus (vaccine or infection) is to initially produce immunoglobulin (Ig)M antibodies, followed by IgG antibodies as the immune response matures. Immunoglobulin A antibodies are also produced in response to an antigenic stimulus, but, because these are most commonly mucosal antibodies, most of the data on COVID-19 vaccination pertain to anti-S IgG.

Several studies have evaluated the maternal anti-S response to vaccination during pregnancy. Initial studies of third-trimester vaccination among 122 individuals who delivered at or near term demonstrated that vaccine-induced antibodies are identified in umbilical cord blood as early as 16 days after the first dose of an mRNA vaccine.12 Other data have identified a linear correlation between maternal IgG levels at delivery and umbilical cord or neonatal IgG levels.12,13

When examining the antibody response to vaccination across all trimesters of vaccination, a cohort study of 1,359 vaccinated individuals who delivered term and late preterm neonates found that anti-S antibodies are detectable at delivery regardless of gestational age at the time of vaccine initiation, as long as individuals were fully vaccinated (defined as at least 2 weeks elapsed since the last vaccine dose) at delivery. The peak maternal and umbilical cord anti-S antibody at delivery was identified with vaccine initiation in the early third trimester, findings that are substantiated in another cohort study (Fig. 2).14,15 These data should not be interpreted to suggest that third-trimester vaccination is the optimal time of vaccination. One study excluded deliveries at less than 34 weeks of gestation, and the other excluded deliveries at less than 37 weeks. Importantly, in the clinical setting, gestational age at birth cannot be predicted. Waiting for third-trimester vaccination only delays maternal protection, the primary indication for vaccination in pregnancy, and may also result in suboptimal neonatal protection.

Fig. 2.:
Maternal and umbilical cord blood anti-spike immunoglobulin G (IgG) levels at delivery among neonates born at more than 34 weeks of gestation, categorized by gestational age at coronavirus disease 2019 (COVID-19) vaccine initiation. A. All vaccinated women at delivery. Maternal anti-spike IgG levels at the time of delivery binned by gestational age or prepregnancy weeks at dose 1 of vaccination. Blue circles depict women fully vaccinated by delivery; red circles indicate women not fully vaccinated by delivery. Moderna (mRNA-1273) vaccine (n=299), Pfizer-BioNTech (BNT162b2) vaccine (n=1,007), and Johnson & Johnson/Janssen (J&J/Janssen) vaccine (n=33). B. Neonates born to all vaccinated women. Umbilical cord anti-spike IgG levels categorized by maternal gestational age or prepregnancy weeks at dose 1 of vaccination. Blue circles depict cord blood samples from neonates of women fully vaccinated by delivery; red circles indicate cord blood samples from neonates of women not fully vaccinated by delivery. Moderna vaccine (n=301), Pfizer-BioNTech vaccine (n=1,008), and J&J/Janssen (n=34). Modified from Yang YJ, Murphy EA, Singh S, Sukhu AC, Wolfe I, Adurty S, et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol 2022;139:373–80. doi: 10.1097/AOG.0000000000004693

Another question is whether the immediate and long-term antibody responses to COVID-19 vaccination are affected by the pregnant state. In one cohort study of pregnant and reproductive-aged nonpregnant individuals, the initial anti-S IgG antibody response was not different between the groups.16 Another study, however, has noted some subtle differences in the initial immunologic response that may be attributable to pregnancy.17 Longitudinal data regarding how the anti-S IgG antibody response wanes over time demonstrate no differences over 6–8 months for individuals vaccinated in pregnancy compared with reproductive-aged nonpregnant individuals. Differences are noted in the IgA peak and longitudinal response by pregnancy state, but the implications of these findings are unknown because clinical follow-up was not included in these studies.16


In pregnancy, COVID-19 vaccination decreases the risks of and complications arising from SARS-CoV-2 infection. In a study of 10,000 pregnant individuals cared for in a single health system in Louisiana during the peak of the Delta variant, COVID-19 vaccination significantly reduced the risk of severe or critical COVID-19 illness, from 0.66% to 0.08%.18 Specifically, none of the 1,332 vaccinated pregnant individuals in the study required supplemental oxygen or ICU admission; however, there was one maternal death, five ICU admissions, and six stillbirths among the 8,760 unvaccinated pregnant individuals with COVID-19.

Population-based data from other countries have similarly demonstrated the maternal benefit of vaccination in pregnancy. In Scotland, where most patients had an mRNA-based vaccine, the relative burden of COVID-19 fell on unvaccinated pregnant individuals. Whereas 77% of all COVID-19 cases occurred in unvaccinated pregnant individuals, 91% of all hospital admissions occurred in unvaccinated individuals, and 98% of all critical care admissions occurred in unvaccinated individuals.19 In a cohort of 28,000 Israeli pregnant individuals, the efficacy of mRNA-based COVID-19 vaccination was estimated to be 96% in the first 2 months after individuals were considered to be fully vaccinated (at least 7 days after the second dose). Vaccine efficacy against hospitalization due to COVID-19 was approximately 89% at a time in which the circulating SARS-CoV-2 variants were the original strain and the Alpha variant.20

In a recent study of 4,517 COVID-19–related emergency department or urgent care visits by pregnant individuals in the United States, COVID-19 vaccination reduced the risk of needing medical evaluation by 75–85% during the Delta wave, with more variable protection observed during the Omicron wave.21 These authors also demonstrate efficacy of COVID-19 vaccination (primary series with or without a monovalent booster) against COVID-19–related hospitalization, with 96–99% efficacy during the Delta wave and 86% efficacy during the Omicron wave among individuals who received the last COVID-19 vaccine dose within 150 days.

An outstanding question is whether the efficacy of vaccination is different in pregnant individuals compared with postpartum or nonpregnant individuals. In a study of almost 20,000 individuals in Norway during the Delta and early Omicron periods, the risks of COVID-19 were not different among individuals fully vaccinated in pregnancy, fully vaccinated postpartum after receiving one dose of vaccine in pregnancy, or fully vaccinated outside of pregnancy and postpartum.22

The overall benefits of COVID-19 vaccination in pregnancy are illustrated in Box 1.

Box 1.

Clinical Benefits of Achieving Coronavirus Disease 2019 (COVID-19) Fully Vaccinated Status During Pregnancy

Maternal benefits

Decreases in:

  • ED or urgent care visits
  • COVID-19–related hospitalization
  • Critical care or intensive care hospitalization

Obstetric benefits

Decreases in:

  • Preterm birth
  • Stillbirth

Infant benefits

Decreases in:

  • SARS-CoV-2 infection
  • COVID-19–related hospitalizations

ED, emergency department; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.


Data generated both from real-world efficacy as well as antibody response to booster doses in pregnancy demonstrate the importance of boosting and remaining up-to-date with vaccine-schedule recommendations. Much of the available data regarding the benefit attributable to a booster dose in pregnancy have been generated with the monovalent booster.

Two studies have investigated the effects of receiving a booster dose in the third trimester, with completion of the initial vaccination series in pregnancy or prepregnancy. Both studies demonstrate that the highest maternal antibody levels are generated with third-trimester boosting, higher than completing the primary series in pregnancy, and result in effective transfer to the neonate.14,23 Similar findings are also noted with boosting in the second trimester.24 Whether the higher neonatal antibodies correlate with lower risks of SARS-CoV-2 infection or longer time of protection for the neonate has yet to be determined, because the level of protective antibody needed is unknown.

However, the primary goal of receiving a booster dose remains for maternal protection, and a retrospective cohort study from Israel provides the greatest argument for the benefit of a booster dose in pregnancy. This nationwide cohort study examined hospitalizations during pregnancy for symptomatic SARS-CoV-2 infections in both the Delta and Omicron waves, stratified by vaccinations received: none, primary series completed, or primary series and booster completed. The authors demonstrate several key findings. First, although completion of the primary vaccine series decreased the risks of hospitalization during the Delta wave, this benefit was eliminated during the Omicron wave. Recipients of three doses of a COVID-19 vaccine had the lowest rates of hospitalization for any symptomatic disease as well as for severe disease during both variant waves. Finally, during the Omicron period, receiving a third vaccine dose resulted in significantly improved vaccine effectiveness against hospitalization compared with two doses only.25 (Fig. 3).

Fig. 3.:
Risk of hospitalization with SARS-CoV-2 during pregnancy, stratified by vaccination status and predominant variant, in Israel. Cumulative incidence curves comparing the two study periods (Delta period on the left [A] and Omicron period on the right [B]) for hospitalizations with a diagnosis of SARS-CoV-2 infection in pregnant women, by vaccination status (third vaccine-green line, second vaccine-orange line, and unvaccinated-blue line). Reprinted from Guedalia J, Lipschuetz M, Calderon-Margalit R, Cohen SM, Goldman-Wohl D, Kaminer T, Melul E, Shefer G, Sompolinsky Y, Walfisch A, Yagel S, Beharier O. Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel. Nat Commun. 2022 Nov 15; 13(1):6961. doi: 10.1038/s41467-022-34605-x. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format. To view a copy of this license, visit

Finally, recent data from the CDC also demonstrate the clinical effectiveness of the bivalent booster in nonpregnant adults. Compared with adults aged 18–49 years who have received at least two doses of an mRNA-based COVID vaccine but have not received a bivalent booster, adults who are up-to-date with the bivalent booster recommendation had an approximately 50% lower risk of symptomatic COVID-19 illness.26


The passive transfer of antibodies across the placental circulation results in protection against COVID-19 in infants. In a large U.S. cohort of infants younger than age 6 months spanning the Delta and Omicron waves, achieving a status of full vaccination while pregnant (delivery at least 2 weeks after the second dose of an mRNA-based vaccine) decreased the risk of infant hospitalization due to COVID-19 by approximately 50%.27 Vaccination at more than 20 weeks of gestation further decreased the risk of infant hospitalization up to 69%.27 These findings have been corroborated in a large Norwegian cohort of infants, where maternal full vaccination decreased the risk of any COVID-19 illness in infants by 70% during the Delta-predominant period and by 33% during the Omicron-predominant period28 (Box 1).

One question that may arise when counseling patients is whether SARS-CoV-2 infection in pregnancy confers a similar antibody-transfer benefit. One study comparing durability of passively transferred antibodies elicited from maternal vaccination (without natural SARS-CoV-2 infection in pregnancy) or maternal infection (without subsequent vaccination) demonstrated that 57% of 6-month-old infants of vaccinated individuals had detectable antibodies as compared with only 8% of infants of individuals with SARS-CoV-2 infection in pregnancy. These data do not address the incidence of clinical COVID-19 illness in infants, but they do indicate more durable antibodies, which likely translates to lower burden of disease among infants born to individuals vaccinated during pregnancy compared with those who had a natural SARS-CoV-2 infection.29


In addition to decreasing the risk of acquiring SARS-CoV-2 infection or developing severe COVID-19, receipt of a COVID-19 vaccine has also been associated with decreased risks of stillbirth or preterm delivery. Whether these improvements in perinatal outcomes are due to avoiding COVID-19 or whether vaccination is a marker for other healthy behaviors during pregnancy is unclear but deserves further study.30 A meta-analysis has demonstrated similar findings, with a 15% reduction in risk of stillbirth noted and a non–statistically significant decrease in preterm delivery (spontaneous and medically indicated both included) of up to 10%.31 Overall, the data are clear that COVID-19 vaccination is not associated with worsening of perinatal outcomes. Whether it improves perinatal outcomes, beyond avoiding the adverse outcomes associated with COVID-19 in pregnancy, is not well-established (Box 1).


Given the data available, the primary benefit of vaccination remains maternal protection and prevention of COVID-19 during pregnancy, averting the risks of severe maternal disease and risks of preterm delivery or stillbirth. Achieving this goal requires that individuals be fully vaccinated against COVID-19 as soon as possible, especially because no data exist to suggest that maternal protection is superior with vaccination at a particular gestational age. Although the absolute number of antibodies transferred to the neonate varies based on both maternal gestational age at vaccination and gestational age at delivery, the highest number of antibodies transferred to the neonate arises from first-trimester or prepregnancy vaccination and third-trimester booster dose.14,32 Because patients cannot predict their gestational age at delivery, deferring vaccination to the second or third trimester to optimize neonatal antibody levels at delivery is ill-advised and not supported by the available literature. One study has demonstrated that neonates born to fully vaccinated individuals, including those with first-trimester vaccination, have similar or higher umbilical cord antibodies than neonates born to individuals who initiated vaccination in the third trimester but are not fully vaccinated before delivery.14

Finally, many patients inquire about the utility of measuring anti-S antibodies generated from prior vaccination or infection to inform the timing of COVID-19 vaccination in pregnancy. Because there is no known level of anti-S antibody that is protective against COVID-19 (also known as the immune correlate of protection), and because the immunologic response to vaccination and a SARS-CoV-2 challenge extends beyond a quantitative amount of anti-S antibody, this approach is not recommended. In addition, the role of mucosal (IgA) immunity or T cell immunity in long-term protection is not clearly defined either. Therefore, the vaccine schedule as set by the CDC, informed by clinical trials and real-world data, is the optimal approach to determining timing of vaccination both during and outside of pregnancy.


The CDC recommends consideration for waiting up to 3 months to receive a dose of a COVID-19 vaccine after confirmed SARS-CoV-2 infection.11 This waiting period should be informed by personal risk of severe COVID-19 (for which pregnancy is a risk factor, in addition to any patient-specific comorbidities), community transmission levels of SARS-CoV-2 infection, and circulating SARS-CoV-2 variants in the community. The rationale for deferring vaccination up to 3 months is based on the low re-infection rate documented across many populations within 3 months of confirmed SARS-CoV-2 infection. However, this is not a recommended or mandatory waiting period, and antibodies produced from natural infection wane quickly. In a large cohort of adult patients hospitalized with COVID-19, vaccination 3–6 months before hospitalization provided more protection against hospitalization than natural SARS-CoV-2 infection 3–6 months prior.33 Primary vaccination or boosting in pregnancy after prior SARS-CoV-2 infection results in high maternal and umbilical cord antibody levels at delivery.14,34 Therefore, administration of a primary dose or a booster dose, even after SARS-CoV-2 infection, is recommended for optimal protection against COVID-19 in pregnancy.


A wealth of data has accumulated to demonstrate the safety of COVID-19 vaccination in pregnancy, with most of the data reflecting the use mRNA-based vaccines. Areas of theoretical concern have included the effects of vaccination on risks of miscarriage, stillbirth, preterm delivery, congenital anomalies, and small-for-gestational-age neonates. These concerns have been refuted with data. Risks of miscarriage at less than 20 weeks of gestation are not different among individuals who did and did not receive COVID-19 vaccination in the 4 weeks before miscarriage.35 Data from v-safe, a CDC registry created to capture patient-reported adverse outcomes after COVID-19 vaccination, show a miscarriage rate of 14% between 6 and 20 weeks of gestation among individuals who received at least one dose of a COVID-19 vaccine, a rate that is consistent with population-based rates of miscarriage.36 These data have been substantiated with additional data from Norway and Scotland.37,38 Vaccination against COVID-19 is also not associated with stillbirth, preterm delivery, small-for-gestational-age neonates, or congenital anomalies.39–41 Data on adverse pregnant outcomes after a monovalent booster are similarly reassuring.42 Finally, adverse peripartum outcomes resulting from COVID-19 vaccination in pregnancy also have not been demonstrated.43

Patients may also inquire about the frequency of vaccine side effects. A large study of more than 12,000 pregnant individuals enrolled in the v-safe registry reported that the most common side effect after each mRNA dose was injection-site pain (88% after dose 1, 92% after dose 2).44 Self-reported fever occurred in 4% after dose 1 and in 35% after dose 2. Although this frequency may seem high, a fever of 38.0°C (100.4°F) or higher occurred among only 8% of all participants. In another study of almost 8,000 individuals self-reporting side effects, some of whom may also have contributed data to the v-safe study, fever occurred in approximately 5% of individuals after dose 1 and, at most, in 20% of individuals after dose 2.45 In that study, the highest mean temperature was 38.1°C (100.6°F) after dose 1 and 38.2°C (100.7°F) after dose 2. Follow-up data from a similarly designed study of monovalent booster doses demonstrated that more than 90% of pregnant individuals receiving booster doses had local injection-site reactions but were less likely to report fevers, myalgias, and headache as compared with nonpregnant or lactating individuals.46

Rare adverse events after COVID-19 vaccination have also been tracked. A large study from the Vaccine Safety Datalink registry of more than 45,000 pregnant individuals vaccinated against COVID-19 demonstrated that fewer than 1% of vaccinated individuals have had an acute event, most commonly fever, malaise or fatigue, local reactions, or lymphadenopathy or lymphadenitis. Serious acute events, such as venous sinus thrombosis, encephalitis or myelitis, Guillain Barre syndrome, myocarditis or pericarditis, or pulmonary embolism, did not occur more frequently in pregnant vaccinated individuals than in pregnant unvaccinated individuals.47


The data on COVID-19 vaccination in pregnancy clearly demonstrate that vaccination averts maternal morbidity from COVID-19. Vaccination also decreases the risk of stillbirth, may decrease the risk of preterm delivery, and decreases the risk of neonatal COVID-19 and resultant hospitalization. Vaccination against COVID-19 during pregnancy is safe, with no increased risks of adverse events and a side-effect profile that is comparable with that in the general population. No documented adverse pregnancy outcomes, such as miscarriage, stillbirth, or preterm delivery, have been attributed to COVID-19 vaccination. COVID-19 vaccination is safe, effective, and a powerful tool to prevent maternal and neonatal morbidity.


1. Razzaghi H, Meghani M, Crane B, Ellington S, Naleway AL, Irving SA, et al. Receipt of COVID-19 booster dose among fully vaccinated pregnant individuals aged 18 to 49 years by key demographics. JAMA 2022;327:2351–4. doi: 10.1001/jama.2022.6834
2. Razzaghi H, Yankey D, Vashist K, Lu PJ, Kriss JL, Nguyen KH, et al. COVID-19 vaccination coverage and intent among women aged 18-49 years by pregnancy status, United States, April-November 2021. Vaccine 2022;40:4554–63. doi: 10.1016/j.vaccine.2022.06.029
3. Centers for Disease Control and Prevention. COVID data tracker: COVID-19 vaccination among pregnant people aged 18-49 years overall, by race and ethnicity, and date reported to CDC - vaccine Safety Datalink,* United States. Accessed January 10, 2023.
4. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1641–7. doi: 10.15585/mmwr.mm6944e3
5. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. N Engl J Med 2021;385:1761–73. doi: 10.1056/NEJMoa2110345
6. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021;385:1774–85. doi: 10.1056/NEJMoa2113017
7. Centers for Disease Control and Prevention. COVID-19 vaccines while pregnant or breastfeeding. Accessed January 12, 2022.
8. American College of Obstetricians and Gynecologists. COVID-19 vaccination considerations for obstetric–gynecologic care. Accessed November 23, 2022.
9. Society for Maternal-Fetal Medicine. Coronavirus (COVID-19) and pregnancy: what maternal-fetal medicine subspecialists need to know. Accessed November 23, 2022.
10. Centers for Disease Control and Prevention. Use of COVID-19 vaccines in the United States. Accessed February 1, 2022.
11. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Accessed November 23, 2022.
12. Prabhu M, Murphy EA, Sukhu AC, Yee J, Singh S, Eng D, et al. Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstet Gynecol 2021;138:278–80. doi: 10.1097/AOG.0000000000004438
13. Beharier O, Plitman Mayo R, Raz T, Nahum Sacks K, Schreiber L, Suissa-Cohen Y, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest 2021;131:150319. doi: 10.1172/JCI150319
14. Yang YJ, Murphy EA, Singh S, Sukhu AC, Wolfe I, Adurty S, et al. Association of gestational age at coronavirus disease 2019 (COVID-19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord antibody levels at delivery. Obstet Gynecol 2022;139:373–80. doi: 10.1097/AOG.0000000000004693
15. Rottenstreich A, Zarbiv G, Oiknine-Djian E, Vorontsov O, Zigron R, Kleinstern G, et al. Timing of SARS-CoV-2 vaccination during the third trimester of pregnancy and transplacental antibody transfer: a prospective cohort study. Clin Microbiol Infect 2022;28:419–25. doi: 10.1016/j.cmi.2021.10.003
16. Prabhu M, Yang YJ, Johnston CD, Murphy EA, Ketas TJ, Diaz-Tapia R, et al. Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons. Am J Obstet Gynecol MFM 2023;5:100796. doi: 10.1016/j.ajogmf.2022.100796
17. Atyeo C, DeRiso EA, Davis C, Bordt EA, De Guzman RM, Shook LL, et al. COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. Sci Transl Med 2021;13:eabi8631. doi: 10.1126/scitranslmed.abi8631
18. Morgan JA, Biggio JRJ, Martin JK, Mussarat N, Chawla HK, Puri P, et al. Maternal outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated compared with unvaccinated pregnant patients. Obstet Gynecol 2022;139:107–9. doi: 10.1097/AOG.0000000000004621
19. Stock SJ, Carruthers J, Calvert C, Denny C, Donaghy J, Goulding A, et al. SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. Nat Med 2022;28:504–12. doi: 10.1038/s41591-021-01666-2
20. Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med 2021;27:1693–5. doi: 10.1038/s41591-021-01490-8
21. Schrag SJ, Verani JR, Dixon BE, Page JM, Butterfield KA, Gaglani M, et al. Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. JAMA Netw Open 2022;5:e2233273. doi: 10.1001/jamanetworkopen.2022.33273
22. Magnus MC, Håberg SE, Carlsen EØ, Kwong JC, Buchan SA, Fell DB. Pregnancy status at the time of COVID-19 vaccination and incidence of SARS-CoV-2 infection. Clin Infect Dis official Publ Infect Dis Soc America 20222022;8:ciac739. doi: 10.1093/cid/ciac739
23. Rottenstreich A, Zarbiv G, Oiknine-Djian E, Vorontsov O, Zigron R, Kleinstern G, et al. The effect of gestational age at BNT162b2 mRNA vaccination on maternal and neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody levels. Clin Infect Dis 2022;75:e603–10. doi: 10.1093/cid/ciac135
24. Kugelman N, Nahshon C, Shaked-Mishan P, Kleifeld S, Cohen N, Sher ML, et al. Maternal and neonatal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G levels after the Pfizer-BioNTech booster dose for coronavirus disease 2019 (COVID-19) vaccination during the second trimester of pregnancy. Obstet Gynecol 2022;140:187–93. doi: 10.1097/AOG.0000000000004867
25. Guedalia J, Lipschuetz M, Calderon-Margalit R, Cohen SM, Goldman-Wohl D, Kaminer T, et al. Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel. Nat Commun 2022;13:6961. doi: 10.1038/s41467-022-34605-x
26. Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection — increasing community access to testing program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep 2022;71:1526–30. doi: 10.15585/mmwr.mm7148e1
27. Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Pannaraj PS, et al. Maternal vaccination and risk of hospitalization for covid-19 among infants. N Engl J Med 2022;387:109–19. doi: 10.1056/NEJMoa2204399
28. Carlsen EØ, Magnus MC, Oakley L, Fell DB, Greve-Isdahl M, Kinge JM, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med 2022;182:825–31. doi: 10.1001/jamainternmed.2022.2442
29. Shook LL, Atyeo CG, Yonker LM, Fasano A, Gray KJ, Alter G, et al. Durability of anti-spike antibodies in infants after maternal COVID-19 vaccination or natural infection. JAMA 2022;327:1087–9. doi: 10.1001/jama.2022.1206
30. Hui L, Marzan MB, Rolnik DL, Potenza S, Pritchard N, Said JM, et al. Reductions in stillbirths and preterm birth in COVID-19 vaccinated women: a multi-center cohort study of vaccination uptake and perinatal outcomes. Am J Obstet Gynecol 2022;3:S000200882–93781. doi: 10.1016/j.ajog.2022.10.040
31. Prasad S, Kalafat E, Blakeway H, Townsend R, O'Brien P, Morris E, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun 2022;13:2414. doi: 10.1038/s41467-022-30052-w
32. Atyeo CG, Shook LL, Brigida S, De Guzman RM, Demidkin S, Muir C, et al. Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms. Nat Commun 2022;13:3571. doi: 10.1038/s41467-022-31169-8
33. Bozio CH, Grannis SJ, Naleway AL, Ong TC, Butterfield KA, DeSilva MB, et al. Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. MMWR Morb Mortal Wkly Rep 2021;70:1539–44. doi: 10.15585/mmwr.mm7044e1
34. Nevo L, Cahen-Peretz A, Vorontsov O, Frenkel R, Kabessa M, Cohen SM, et al. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. Am J Obstet Gynecol 2022;227:486.e1–10. doi: 10.1016/j.ajog.2022.04.010
35. Kharbanda EO, Haapala J, DeSilva M, Vazquez-Benitez G, Vesco KK, Naleway AL, et al. Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA 2021;326:1629–31. doi: 10.1001/jama.2021.15494
36. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, et al. Receipt of mRNA covid-19 vaccines and risk of spontaneous abortion. N Engl J Med 2021;385:1533–5. doi: 10.1056/NEJMc2113891
37. Calvert C, Carruthers J, Denny C, Donaghy J, Hillman S, Hopcroft LEM, et al. A population-based matched cohort study of early pregnancy outcomes following COVID-19 vaccination and SARS-CoV-2 infection. Nat Commun 2022;13:6124. doi: 10.1038/s41467-022-33937-y
38. Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fell DB, Håberg SE. Covid-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med 2021;385:2008–10. doi: 10.1056/NEJMc2114466
39. Lipkind HS, Vazquez-Benitez G, DeSilva M, Vesco KK, Ackerman-Banks C, Zhu J, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth—eight integrated health care organizations, United States, December 15, 2020–July 22, 2021. MMWR Morb Mortal Wkly Rep 2022;71:26–30. doi: 10.15585/mmwr.mm7101e1
40. Ruderman RS, Mormol J, Trawick E, Perry MF, Allen EC, Millan D, et al. Association of COVID-19 vaccination during early pregnancy with risk of congenital fetal anomalies. JAMA Pediatr 2022;176:717–9. doi: 10.1001/jamapediatrics.2022.0164
41. Magnus MC, Örtqvist AK, Dahlqwist E, Ljung R, Skår F, Oakley L, et al. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. JAMA 2022;327:1469–77. doi: 10.1001/jama.2022.3271
42. Moro PL, Olson CK, Zhang B, Marquez P, Strid P. Safety of booster doses of coronavirus disease 2019 (COVID-19) vaccine in pregnancy in the vaccine adverse event reporting system. Obstet Gynecol 2022;140:421–7. doi: 10.1097/AOG.0000000000004889
43. Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK, et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA 2022;327:1478–87. doi: 10.1001/jama.2022.4255
44. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA covid-19 vaccine safety in pregnant persons [published erratum appears in N Engl J Med 2021;385:1536]. N Engl J Med 2021;384:2273–82. doi: 10.1056/NEJMoa2104983
45. Kachikis A, Englund JA, Singleton M, Covelli I, Drake AL, Eckert LO. Short-term reactions among pregnant and lactating individuals in the first wave of the COVID-19 vaccine rollout. JAMA Netw Open 2021;4:e2121310. doi: 10.1001/jamanetworkopen.2021.21310
46. Kachikis A, Englund JA, Covelli I, Frank Y, Haghighi C, Singleton M, et al. Analysis of vaccine reactions after COVID-19 vaccine booster doses among pregnant and lactating individuals. JAMA Netw Open 2022;5:e2230495. doi: 10.1001/jamanetworkopen.2022.30495
47. DeSilva M, Haapala J, Vazquez-Benitez G, Vesco KK, Daley MF, Getahun D, et al. Evaluation of acute adverse events after covid-19 vaccination during pregnancy. N Engl J Med 2022;387:187–9. doi: 10.1056/NEJMc2205276

Supplemental Digital Content

© 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.